Blog

FDA Breakthrough Device: Does Your MedTech Qualify?
The FDA Breakthrough Device designation can change the trajectory of a medical device program. For a startup racing toward a first-in-human milestone, it signals to investors, partners, and the agency itself that your technology addresses a genuine unmet need. But the program is selective, the criteria are specific, and designation alone does not guarantee authorization. This article covers exactly what qualifies, how to apply, and what breakthrough status actually means for your clinical development timeline.

What the FDA Breakthrough Devices Program Actually Is

The Breakthrough Devices Program is a voluntary FDA program that gives certain medical devices and device-led diagnostics priority interaction and review. Established under the 21st Century Cures Act and formalized in FDA guidance, it was designed to accelerate the development and review of devices that provide more effective treatment or diagnosis of serious or life-threatening conditions.

The program does not create a separate regulatory pathway. Devices still go through 510(k), De Novo, or PMA review. What changes is the speed and depth of FDA engagement along the way: more frequent interactions, earlier access to senior reviewers, and a commitment to timely review once a premarket submission arrives.

The scale of the program reflects genuine industry demand. According to the U.S. Food and Drug Administration, 1,246 breakthrough device designations had been granted from the program's launch through December 31, 2025. Of those, 185 had received marketing authorization. That conversion rate matters — and is addressed in detail below.

The Two Eligibility Criteria Your Device Must Meet

Qualifying for breakthrough designation requires satisfying two conditions simultaneously. Both must be present. Meeting only one is not sufficient.

Criterion 1: Serious or Life-Threatening Condition

Your device must be intended to treat or diagnose a disease or condition that is serious or life-threatening. The FDA interprets "serious" broadly — conditions do not have to be immediately fatal to qualify. Chronic conditions that cause substantial impairment, irreversible morbidity, or significant reduction in daily function can meet this threshold.

Conditions that have historically qualified include heart failure, treatment-resistant depression, advanced-stage cancers, severe neurological disorders, and conditions with no adequate alternative therapy. The core question is whether the condition imposes a meaningful burden on patients and whether current options fall short.

Criterion 2: More Effective Than Available Alternatives

This is where most applications succeed or fail. Your device must provide for more effective treatment or diagnosis of the condition compared to currently available alternatives. The FDA evaluates this on one or more of the following grounds:
- Represents a breakthrough technology with no approved or cleared alternatives
- Offers significant advantages over existing approved or cleared alternatives, including improved diagnosis, treatment, or monitoring
- Availability is in the best interest of patients, particularly when the condition is serious and no alternative exists
"More effective" does not require clinical proof at the time of designation. Preclinical data, mechanism-of-action arguments, and a credible scientific rationale can support the request. The FDA is making a preliminary judgment about potential — not a final determination about efficacy.

When to Apply and What to Submit

Sponsors can request breakthrough designation at any point in the development process, including before an Investigational Device Exemption (IDE) is in place. Early application is generally advisable because the benefit of enhanced FDA interaction is most valuable before your protocol is finalized and your trial is underway.

The designation request is submitted as a separate administrative submission — not as part of a Pre-Sub or IDE. It should include:
- A description of the device and its intended use
- The serious condition the device addresses
- The basis for believing the device meets the "more effective" criterion, supported by available preclinical or clinical data
- A description of the current standard of care and why it is inadequate
The FDA has 60 calendar days to respond. In practice, the agency either grants designation, denies it with explanation, or requests additional information. Denial does not close the door permanently; sponsors can reapply with additional supporting data.

What Breakthrough Designation Actually Gets You

Designation is a process benefit, not a regulatory shortcut. Here is what it concretely provides:

Increased interaction with FDA. Designated devices receive priority access to FDA staff for meetings, written feedback, and dispute resolution. This matters most during protocol design, when early alignment on endpoints and study design can prevent costly amendments later.

Timely review commitment. Once a premarket submission is filed, the FDA commits to a review timeline faster than standard pathways. For PMA applications, the target review time for breakthrough devices is shorter than the standard 180-day target.

Senior staff involvement. Breakthrough programs bring senior FDA reviewers into the process earlier, which can reduce the back-and-forth that extends standard reviews.

Potential for rolling review. Sponsors can submit completed sections of a PMA as they become available rather than waiting to compile the full package — compressing the overall submission-to-decision timeline.

What designation does not provide: guaranteed approval, relaxed safety standards, or exemption from the clinical evidence requirements that apply to your device class. The FDA still expects rigorous, well-controlled clinical data.

The Gap Between Designation and Authorization

This is the number that deserves more attention than most articles give it. A 2025 report published on pubmed.ncbi.nlm.nih.gov analyzed FDA data from January 1, 2016 through September 30, 2024, covering 1,041 breakthrough designations and 127 marketing authorizations during that period. The authorization rate was 12.2%.

That figure does not mean the program fails 87.8% of devices. Many designated devices are still in active development, and the pipeline takes years to move from designation to submission. But the number does underscore that designation is a starting point, not a finish line.

The same 2025 report found that among the 127 authorized breakthrough devices in that dataset, 75 were therapeutic devices — representing 59.1% of all authorized breakthrough products. Diagnostics and monitoring devices made up the remainder. If your device is therapeutic, you are working in the category that has produced the most authorizations under this program.

How Breakthrough Designation Connects to Your FIH Strategy

For a pre-IDE startup, breakthrough designation and first-in-human execution are parallel tracks, not sequential ones. You can pursue designation while your clinical program is being structured. The FDA interactions that come with designation are most useful when your protocol is still being designed — which is precisely when you can act on them.

This is where the choice of CRO and clinical geography matters directly. The FDA accepts foreign clinical data under 21 CFR 812.28 when it is collected under ISO 14155 architecture and submitted with appropriate documentation. First-in-human studies conducted in Latin America, structured to that standard, generate data that supports a U.S. IDE, 510(k), De Novo, or PMA submission.

bioaccess® builds every protocol to ISO 14155 architecture and structures data per FDA 21 CFR 812.28. The FIH-12™ program delivers a submission-ready clinical evidence package within a 12-month structured timeline, with ethics and regulatory approvals in Panama, El Salvador, Chile, and the Dominican Republic observed in 30 to 90 days. For a startup that has just received breakthrough designation and needs first human data before the next funding round, that timeline is the relevant comparison point against the 6 to 12 months that U.S. or EU site approvals typically require.

The Axoft case study illustrates this directly: a Panama first-in-human program that preceded a $55M Series A. enVVeno Medical used a LATAM FIH foundation to build the evidence base for the first-ever FDA IDE for a non-surgical replacement venous valve. These are documented programs, not hypothetical outcomes.

For device sponsors working through coronary or vascular indications, the CeloNova BioSciences COBRA PzF stent program and the ClarVista Medical program — which ended in an Alcon acquisition — show how Latin America-executed clinical evidence supports the full regulatory arc from first-in-human through commercial exit.

Common Reasons Designation Requests Are Denied

Understanding why requests fail is as useful as understanding the criteria. The most frequent reasons include:

Inadequate characterization of the condition. If the submission does not clearly establish that the target condition is serious or life-threatening, the FDA has no basis to grant designation. This is as much a writing and framing problem as a scientific one.

Weak differentiation from existing alternatives. If approved or cleared alternatives exist and the submission does not explain specifically how the device is more effective, the FDA will deny the request. "Novel technology" is not sufficient without a mechanism-based or data-supported argument for superiority or advantage.

Indication scope mismatch. Requests that describe a broad indication when the clinical data supports only a narrow one create credibility problems. Narrowing the intended use to match available evidence often strengthens a request.

Premature submission without supporting data. Preclinical data can be sufficient, but a request with no scientific rationale beyond the device description is unlikely to succeed. Even early bench or animal data that speaks to mechanism or safety profile strengthens the argument.

After Designation: Keeping the Benefits Active

Breakthrough designation does not expire, but the benefits depend on active engagement. Sponsors who fail to schedule interactions with FDA, miss the opportunity to align on study design early, or submit a premarket application without taking advantage of rolling review are leaving the program's value on the table.

The FDA can also withdraw designation if the device no longer meets the criteria — for example, if a new alternative receives clearance that addresses the same unmet need. Monitoring the competitive landscape and maintaining regular FDA communication protects the designation's value over time.

Frequently Asked Questions

What is the FDA Breakthrough Devices Program?
The FDA Breakthrough Devices Program is a voluntary program that provides priority interaction and review for medical devices intended to treat or diagnose serious or life-threatening conditions more effectively than currently available alternatives. It does not create a separate regulatory pathway but accelerates FDA engagement throughout development and review.

What conditions qualify a device for breakthrough designation?
The target condition must be serious or life-threatening, which includes conditions causing substantial impairment, irreversible morbidity, or significant reduction in daily function. Conditions do not need to be immediately fatal to qualify.

Does a device need clinical data to apply for breakthrough designation?
No. Sponsors can apply at any stage of development, including before an IDE is in place. Preclinical data, mechanism-of-action arguments, and a credible scientific rationale are sufficient to support a designation request. Clinical proof is not required at the time of application.

How long does the FDA take to respond to a breakthrough designation request?
The FDA has 60 calendar days to respond. The agency will either grant designation, deny it with explanation, or request additional information.

What is the authorization rate for breakthrough-designated devices?
A 2025 report published on pubmed.ncbi.nlm.nih.gov found that between January 2016 and September 2024, 12.2% of designated devices had received marketing authorization. Many designated devices remain in active development, so this figure reflects the pipeline's stage distribution, not program failure.

Can first-in-human data from Latin America support a US breakthrough device submission?
Yes. The FDA accepts foreign clinical data under 21 CFR 812.28 when collected under ISO 14155 architecture with appropriate documentation. First-in-human studies conducted in Latin America through a program structured to those standards generate data accepted for U.S. IDE, 510(k), De Novo, and PMA submissions.

When should a startup pursue breakthrough designation relative to its FIH program?
Designation and FIH execution can run in parallel. Applying before your protocol is finalized is advisable because the enhanced FDA interaction is most valuable during study design. A CRO with FDA Pre-Sub experience can help align both tracks so the designation benefits directly inform the FIH protocol.

Build the Evidence Package Your Designation Demands

Breakthrough designation opens the door to faster FDA engagement. What you bring through that door is a clinical evidence package. The quality, structure, and FDA-readiness of that package determine whether designation translates into authorization.

bioaccess® structures FIH programs specifically to produce submission-ready evidence under ISO 14155 and FDA 21 CFR 812.28, with observed ethics and regulatory approval timelines of 30 to 90 days across Panama, El Salvador, Chile, and the Dominican Republic. For startups with a breakthrough designation and a funding clock running, that combination of speed and FDA-accepted rigor is the relevant operational question.

Learn more at bioaccessla.com.
September 19, 2026
FDA IDE Approval: Steps After You Submit Your Application
You filed your Investigational Device Exemption application. The submission is in FDA's hands. Now what?

FDA IDE approval is not a single event — it's a structured review sequence that begins the moment your application reaches the Center for Devices and Radiological Health (CDRH). Most first-time sponsors underestimate how many distinct steps follow submission. Understanding each one lets you plan site activation, manage investor expectations, and avoid the delays that derail early-stage programs before they start.

This article walks through every stage of the post-submission process — from the initial administrative screening to the conditions that often accompany approval — and explains how experienced sponsors use that window to prepare for first-in-human execution.

What Happens Immediately After Submission

FDA's review clock starts at receipt. Under 21 CFR 812, the agency has 30 calendar days to approve the IDE, disapprove it, or allow it to take effect by default if no action is taken. That 30-day window sounds fast. In practice, it rarely plays out that cleanly.

The first step is an administrative completeness check. Reviewers confirm that all required sections are present: the investigational plan, risk analysis, device description, manufacturing information, investigator agreements, IRB status, and marketing history. If anything is missing, FDA may place the application on hold or issue a deficiency letter before substantive review even begins.

This administrative phase typically takes 5 to 10 business days. An incomplete submission can cost a sponsor weeks before the scientific review starts.

The 30-Day Review Window

Once the application clears administrative screening, CDRH assigns it to a review division based on device type. The assigned reviewer evaluates the scientific and clinical content: study design, endpoints, patient selection criteria, risk-benefit analysis, and the preclinical evidence supporting the proposed first-in-human use.

FDA may contact the sponsor with questions during this period. Those informal communications don't stop the 30-day clock — but they do require fast responses. A sponsor who takes 10 days to answer a reviewer's question effectively compresses whatever review time remains.

Three outcomes are possible at the end of the window:
- Approval: FDA issues a written approval letter. The IDE is effective, and the sponsor may proceed under the approved protocol.
- Disapproval: FDA issues a written disapproval with specific reasons. The sponsor may request reconsideration or submit an amended application.
- Conditional approval: FDA approves the IDE subject to specific conditions the sponsor must satisfy before or during the study. This is the most common outcome for first-in-human device studies.
Default approval — where FDA takes no action within 30 days and the IDE is deemed approved — does occur. Sponsors should not plan around it. Proceeding on a default approval without written confirmation creates regulatory risk.

Conditional Approval: What It Means and What to Do Next

Conditional approval is not a partial win. It is a full IDE approval with attached requirements. FDA may require protocol amendments, additional preclinical data, modified informed consent language, enhanced safety monitoring, or specific reporting intervals. Each condition carries its own compliance obligation.

Read the approval letter carefully. Some conditions must be satisfied before the first patient is enrolled. Others apply throughout the study. Misreading a pre-enrollment condition as an ongoing obligation — or vice versa — can put the program out of compliance from day one.

Common pre-enrollment conditions include:
- Submission of a final, IRB-approved protocol incorporating FDA's requested modifications
- Confirmation of investigator qualifications at each site
- Submission of a clinical trial insurance policy
- Updated device labeling reflecting the approved indications
Once conditions are satisfied, the sponsor typically notifies FDA in writing. FDA does not issue a separate "conditions cleared" letter in most cases — documenting and maintaining compliance is the sponsor's responsibility.

IDE Amendments and Protocol Changes

IDE approval does not lock the protocol in place. Sponsors frequently need to amend after approval — to add investigators, modify sites, adjust inclusion/exclusion criteria, or update the device design following design freeze confirmation.

Under 21 CFR 812.35, significant changes to the investigational plan, the device, or informed consent require a supplemental IDE submission. FDA reviews significant amendments under the same 30-day framework. Non-significant changes require sponsor notification but not prior FDA approval.

The line between significant and non-significant isn't always obvious. When in doubt, submit. An unapproved significant change can invalidate data collected under the modified protocol — a serious problem if that data is intended for a future PMA or 510(k) submission.

Site Activation After IDE Approval

IDE approval does not authorize patient enrollment. Each investigational site must also receive IRB approval before enrollment begins. In the US, that IRB review runs in parallel with or after the IDE process and adds weeks to the activation timeline.

Site activation involves several parallel workstreams: executing investigator agreements, completing site qualification visits, confirming device importation logistics, training the site team on the protocol and GCP requirements, and verifying that the site's patient population matches the study's eligibility criteria.

For multi-site studies, site activation is often the longest phase between IDE approval and first patient enrolled. A site that passes qualification but takes 8 weeks to complete IRB review and staff training effectively delays the entire program.

This is one reason some sponsors run early feasibility studies outside the US first, using data collected under ISO 14155 and structured per FDA 21 CFR 812.28 to support a subsequent US IDE submission. The enVVeno Medical case study illustrates this path directly: OUS early clinical execution in Latin America generated the evidence package that supported the first-ever FDA IDE for a non-surgical replacement venous valve.

FDA IDE Approval and the OUS Clinical Strategy

For many MedTech startups, IDE approval isn't the starting point for first-in-human data — it's the destination. OUS studies generate the preclinical-to-clinical bridge data that makes the IDE application credible in the first place.

Under FDA 21 CFR 812.28, data from foreign clinical investigations may be accepted in support of an IDE if the studies were conducted under conditions comparable to FDA requirements and the data is submitted in a format FDA can evaluate. ISO 14155 provides the protocol architecture that satisfies this comparability standard.

Running an early feasibility study in Panama, Chile, El Salvador, or the Dominican Republic — where ethics and regulatory approvals are observed in 30 to 90 days — compresses the time between design freeze and first human data by months compared to initiating a US study from scratch. That compression matters when a startup's financial runway is measured in quarters, not years.

The Cook Group multi-site study in Colombia demonstrates what structured OUS execution looks like at scale: 142-plus INVIMA regulatory submissions managed across a multi-site first-in-human artificial venous valve program, with data architecture designed to support US regulatory use.

Reporting Obligations That Begin at Approval

IDE approval activates a set of ongoing reporting obligations that sponsors must maintain throughout the study. These are not optional and are not triggered only by adverse events.

Annual progress reports must be submitted to FDA within 30 days of the IDE anniversary. The report covers enrollment status, adverse events, protocol deviations, and any changes to the investigational plan.

Unanticipated adverse device effects (UADEs) must be reported to FDA and all reviewing IRBs within 10 business days of the sponsor's first receipt of information about the effect. This is a hard deadline. Sponsors who lack a functioning safety monitoring and reporting system before enrollment begins routinely miss it.

IDE withdrawal or termination requires a final report within 30 days. If the study ends early — for any reason — the reporting obligation does not end with it.

Building these reporting workflows before the first patient is enrolled is not administrative overhead. Gaps in IDE reporting history can complicate future submissions.

What the IDE Approval Letter Does Not Cover

A few things sponsors sometimes assume the IDE approval letter addresses — but doesn't:

It does not authorize commercial distribution. An IDE permits clinical investigation only. Selling or distributing the device outside the approved study is a violation of 21 CFR 812, regardless of what the IDE says.

It does not constitute FDA endorsement of the device's safety or effectiveness. Approval means FDA found the proposed study acceptable to proceed — not that the device is safe or effective. This distinction matters for investor communications and for informed consent language.

It does not guarantee a clear path to PMA or 510(k). The study design approved under the IDE must be executed as approved. Data collected under a protocol that deviates from the approved IDE may not be accepted in a subsequent marketing application.

It does not replace IRB approval at each site. IDE approval and IRB approval are both necessary before enrollment. They are separate, parallel requirements.

Using the IDE Approval Window Productively

The period between IDE submission and approval — typically 4 to 8 weeks for a complete, well-prepared application — is not dead time. Sponsors who use it well arrive at approval ready to activate.

During this window, experienced sponsors complete site qualification visits, finalize investigator agreements, confirm device manufacturing readiness, and brief the IRB on the expected protocol. If conditional approval is likely, sponsors can anticipate common conditions and prepare responsive documentation in advance.

For programs that ran OUS early feasibility studies before the IDE submission, this window is often used to close out the OUS data package and prepare FDA-bridging documentation under 21 CFR 812.28. The i-Lumen Scientific retinal therapy program reflects how OUS execution and US regulatory strategy can be sequenced to minimize total time to first US enrollment.

After Approval: The Path to First Patient Enrolled

IDE approval is a regulatory milestone, not a clinical one. The distance between approval and first patient enrolled depends entirely on how well the sponsor managed parallel workstreams during the review period.

Programs that arrive at IDE approval with sites qualified, IRB submissions in progress, and device inventory staged typically enroll their first patient within 8 to 12 weeks of the approval letter. Programs that treat IDE approval as the trigger to begin site activation routinely add 4 to 6 months to that timeline.

The FIH-12™ program at bioaccess® is structured around this reality. Nine workstreams — covering FDA strategy alignment, protocol development, site activation, patient enrollment, data management, and submission-ready evidence package delivery — run in parallel, not in sequence. That parallel architecture is what makes a 12-month protocol-to-evidence-package timeline achievable for programs that would otherwise take 18 to 24 months under a sequential approach.

Frequently Asked Questions

What is FDA's timeline for reviewing an IDE application after submission?
FDA has 30 calendar days from receipt to approve, disapprove, or take no action on an IDE application. Most complete applications receive a written response within that window, though administrative deficiencies can delay the start of substantive review.

What does conditional IDE approval mean?
Conditional approval means FDA has approved the IDE subject to specific requirements the sponsor must satisfy before or during the study. Common conditions include IRB-approved protocol amendments, updated device labeling, or additional preclinical data. The study may not proceed until pre-enrollment conditions are met.

Can I enroll patients immediately after receiving IDE approval?
No. IDE approval authorizes the study but does not replace IRB approval at each investigational site. Each site must receive independent IRB approval before enrolling patients. Site activation, investigator agreements, and staff training must also be completed first.

What reporting obligations does IDE approval trigger?
Sponsors must submit annual progress reports within 30 days of the IDE anniversary, report unanticipated adverse device effects (UADEs) to FDA and reviewing IRBs within 10 business days, and submit a final report within 30 days if the study is terminated.

Can data from OUS studies support an IDE application?
Yes. Under FDA 21 CFR 812.28, data from foreign clinical investigations conducted under conditions comparable to FDA requirements may be accepted in support of an IDE. Studies structured under ISO 14155 satisfy the comparability standard FDA applies.

What happens if I make changes to the protocol after IDE approval?
Significant changes to the investigational plan, the device, or informed consent require a supplemental IDE submission and FDA approval before implementation. Non-significant changes require sponsor notification only. Implementing a significant change without prior FDA approval can invalidate data collected under the modified protocol.

How long does site activation typically take after IDE approval?
Sponsors who begin qualification visits and IRB submissions during the IDE review period typically enroll their first patient within 8 to 12 weeks of approval. Sponsors who begin activation only after receiving the approval letter often add 4 to 6 months to that timeline.

What Comes Next

FDA IDE approval is a milestone you earn through preparation, not one you wait for. The quality of your application determines how quickly FDA can review it. The work you do during the review period determines how quickly you can enroll after approval. And the data architecture you establish before the first patient is enrolled determines whether the evidence package you generate will support a US marketing application.

For sponsors building that architecture from the ground up, visit bioaccess® to understand how the FIH-12™ program structures each workstream — from Pre-Sub alignment through submission-ready evidence delivery — to keep your program on the timeline your investors and board are counting on.

WordPress Category: Navigating Regulatory Landscapes in Latin America
September 18, 2026

Chile ISP clinical trial path for medical devices: investigation vs Exempt Decree No. 25 registro

Sponsors mix two Chile clocks into one bar labeled “ISP.” One clock is Instituto de Salud Pública (ISP) authorization for a medical-device clinical investigation and investigational import. The other is commercial sanitary registration under Chile’s expanding Exempt Decree No. 25 wave. They are not the same petition. Confusing them is how a Santiago FIH plan quietly becomes a 2028 market-access scramble.

I am Julio Martinez-Clark, CEO of bioaccess®. This page is the operator brief for running a medical-device clinical trial in Chile under ISP — and keeping that trial file off the commercial registro track. It is grounded in the live FIH startup clock, fast-track FIH corridor, Chile Exempt Decree No. 25 / ISP registration 2028, and Chile site posts such as Hospital Luis Tisné Santiago. It is not a quote and not legal advice. Confirm current ISP, ethics, and import instructions before you file.

Two Chile files — write them apart first

Investigation file (this page). ISP authorizes the clinical investigation and investigational-device import. An Ethical-Scientific Committee under Law 20.120 still has to sit. Success criterion: authorized research use of the named investigational article at named sites.
Commercial registro file (different Gantt). Exempt Decree No. 25 (published 19 March 2026) expands mandatory ISP sanitary registration across 39 product types, including software as a medical device and multiple IVDs, with transition waves toward 2028/2029. Success criterion: conformity verification / ISP sanitary registration for manufacture, import, marketing, or distribution of covered products after the applicable transition dates.

Live Chile blogs already put a typical ISP investigation review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file. Do not put both on one Gantt labeled “Chile.”

Where Chile sits on the FIH map

Chile is inside Latin America’s fast-track FIH corridor with Panama, El Salvador, and Costa Rica. Published corridor activation band: 15–45 days. Panama remains the documented extreme (~15-day activation; ethics-submission ID in about 3 business days). Chile’s published role in that corridor is different: corridor speed plus top-tier perceived data rigor — the combination sponsors look for when they do not want a “small fast market” discount on the evidence package.

Speed drivers on the live corridor page: efficient ethics and ISP pathways; experienced committees. Cost tier: upper among corridor countries — you pay for depth and perception. Population is still small; feasibility and backup sites matter.

What ISP owns on the trial track

Clinical-investigation authorization. ISP is the investigation desk for device studies in Chile. A named hospital campus on ClinicalTrials.gov is not the ISP applicant and is not the operator of the ISP file.
Investigational-device import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See the regional investigational import guide.
Not commercial registro. Post-Decree 25 market access (technical instruction from ISP within up to 12 months of publication, Spanish IFU/label expectations, tecnovigilancia enrollment) belongs on the commercial track. Keep it off the FIH critical path until first patient is locked.

We will not invent PAHO/WHO Level 4 standing for ISP. All bioaccess® device protocols in this country run under ISO 14155 and the Declaration of Helsinki.

Ethics under Law 20.120

An Ethical-Scientific Committee under Law 20.120 still has to sit. Institutional ethics calendars at Chilean hospitals are real — and they are not ISP. Share committee calendars and hospital research rules with the CRO early. Do not wait for the ISP letter to discover that the committee meets monthly and your Spanish informed-consent text is still in draft.

Operator rule: same protocol version and same Spanish informed-consent text across the ethics packet and the ISP packet. The commercial IFU you will later lock under Decree 25 is not the ethics ICF.

Submission checklist (investigation dossier)

Assemble the universal FIH core once, then layer Chile. Do not invent form codes that are not on live bioaccessla.com pages — use this operator checklist against ISP’s current published requirements at filing time.

Section	What to freeze	Operator check
Protocol	Version, endpoints, stopping rules	Same version for ISP and Ethical-Scientific Committee
Investigator’s brochure / preclinical	Risk profile for first human use	Matches the article on the investigational device list
Informed consent (Spanish)	Ethics-ready castellano	Not the commercial IFU for Decree 25 registro
Insurance	Trial-related injury coverage	Territory names Chile; language matches ethics packet
ISO 14155 monitoring plan	GCP bridge for foreign data	Design for 21 CFR § 812.28 inspectability if a U.S. file is intended
Investigational labeling	For clinical investigation only	Lot/serial traceability matches site accountability
Device / accessory list	Every unit in the accountability log	Quantities match what import will request
Importer of record	Legal name before ethics stamps	Document ties shipment to investigation authorization — not a commercial ISP certificate
Ethics letter (Law 20.120)	Ethical-Scientific Committee outcome	Keep correspondence in one trial master file
ISP investigation authorization	Study authorization + import path	~30 business-day planning band; confirm at filing

Import: investigational units are not the Decree 25 SKU

Name the trial importer before ethics stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational. After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy.

Hand-carry is not the plan. Formal, traceable importation tied to the trial authorization is required across Latin America; Chile is not an exception.

If the Chile FIH must support a U.S. file

Design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States): GCP, independent ethics review, and a device comparable to the version you will put in front of FDA. ISO 14155 is the device GCP bridge. A clean ISP investigation letter does not replace an inspectable trial master file. Eligibility of foreign data under § 812.28 is not a clearance prediction. See the live 812.28 LATAM inspectability page.

Do not smear the hospital — and do not skip ISP

Named Santiago campuses on ClinicalTrials.gov (for example Hospital Luis Tisné, Clínica Colonial) are real hospital strings. They can discuss investigator interest, local visit costs, and ethics calendars. They cannot, by ranking on ClinicalTrials.gov, become your ISP applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR § 812.28 packager. The First-in-Human CRO still owns those workstreams — plus the option to add another Latin American country if one Chilean campus is not the only enrollment fit.

Common rejection / delay patterns

One “ISP” bar for trial and registro. Investigation (~30 business days planning) versus commercial registration (30–90 days planning; Decree 25 waves later) are different files.
Commercial certificate on investigational freight. Decree 25 / sanitary registration paperwork does not clear FIH kits.
Hospital NCT string treated as the regulatory plan. Campus ≠ ISP file.
Importer named after first patient. Import then becomes the critical path.
Waiting for ISP’s Decree 25 technical instruction before any commercial readiness. That is a market-access problem — keep it off the FIH critical path, but do not ignore it for launch planning.

One-page gate before first patient in Chile

Authority map: ISP investigation + Ethical-Scientific Committee (Law 20.120) versus commercial ISP registro under Exempt Decree No. 25 only if launch is truly in scope.
Same protocol version and same Spanish informed-consent text across ethics and ISP packages.
Investigational importer named, with the document that ties the shipment to the investigation authorization.
Device list complete, including accessories.
ISO 14155 file owner who can produce monitoring, accountability, and ethics letters within 48 hours if FDA asks.
Feasibility: real site-level patient flow for your indication — corridor speed does not create patients.

How to obtain ANVISA, COFEPRIS, ANMAT, or Panama MINSA approval for a medical device clinical trial

Sponsors keep asking one stacked question: how do I obtain ANVISA, COFEPRIS, ANMAT, or Panama MINSA approval for a medical device clinical trial? Those four names are not interchangeable stamps. Each one is a different investigation desk, with a different ethics gate, and a different investigational-import story. Treating them as one “LATAM approval” is how a Gantt goes soft.

I am Julio Martinez-Clark, CEO of bioaccess®. This page is a comparison hub for medical-device clinical-investigation authorization in Brazil, Mexico, Argentina, and Panama. It is grounded in live bioaccessla.com posts on the FIH startup clock, investigational import, ANMAT investigation checklist, Mexico’s COFEPRIS reset, and the Panama / El Salvador corridor pages. It is not a quote and not legal advice. Confirm every instrument against each agency’s current published texts before you file.

Write four columns before translators start

Put these four tracks on one page. Do not merge them into a single “regulatory” bar.

Brazil — ANVISA. Agency review of the device clinical investigation, plus ethics (CEP/CONEP), plus a two-layer import path.
Mexico — COFEPRIS. Federal protocol authorization, plus CONBIOÉTICA-linked ethics, plus a research-use import permit.
Argentina — ANMAT. Investigation authorization (not commercial registro), plus independent ethics, plus provincial filings where required.
Panama — MINSA. Ministry of Health investigation track with CNBI-registered ethics — the documented sprinter in the fast corridor.

If the board slide says “we got LATAM approval,” ask which desk, which ethics letter, and which import document.

Same question, four different clocks

Published operator planning bands on the live startup clock (confirm at contracting):

Country / desk	Planning activation band	Why the band looks that way
Panama — MINSA + CNBI ethics	15–45 days (fast corridor)	Ethics-submission ID in about 3 business days on published experience; parallel ethics and regulator work; about 15-day activation achieved in a real program
Mexico — COFEPRIS + ethics	Historically 6–9 months; watchlist with asterisk	Published reset language cuts protocol review toward ~30 days with ethics ~4–6 weeks in parallel — verify measured clocks before you put Mexico in the fast corridor by default
Brazil — ANVISA + CEP/CONEP	6–9 months	Full agency review plus ethics; largest patient pool in the region
Argentina — ANMAT + ethics	6–9 months	Investigation desk with a 90-business-day statutory review target that pauses for RFIs; FIH/EFS often exceeds the target

Panama sits with Chile, El Salvador, and Costa Rica in the 15–45 day corridor. Mexico, Brazil, Colombia, and Argentina sit in the major-market band unless a measured clock proves otherwise.

Brazil — ANVISA (investigation + import are two layers)

For investigational devices, Brazil is a two-layer system on the live import guide:

ANVISA clinical-investigation approval under RDC 837/2023. The Comunicado Especial lists the investigational products and authorized quantities.
Licença de Importação (LI) in Siscomex with ANVISA release at the port. The import rulebook (RDC 81/2008) is under revision — confirm the current instrument before citing it at filing.

Ethics runs through CEP/CONEP. Portuguese certificate-of-insurance language is not optional stationery for that packet. Use the Brazil clinical-trials hub for clocks; do not invent medians here.

Operator check: freeze the investigational product list once. The Comunicado Especial quantities must match what Siscomex will see. A commercial sanitary registration number does not clear FIH freight.

Mexico — COFEPRIS (reset language ≠ measured clock yet)

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is Mexico’s federal health regulator. CONBIOÉTICA is the national bioethics commission. Live COFEPRIS reset coverage already states:

Published direction cuts clinical-trial protocol review from ~120 days toward ~30 days.
An abbreviated pathway in force since 1 September 2025 gives ~30-business-day device decisions for products already authorized by certain reference regulators.
A 15 January 2026 decree amended the Ley General de Salud on clinical-research reform, with COFEPRIS–CONBIOÉTICA coordination.
Regulatory reliance language recognizes evaluations by FDA, EMA, MHRA, and Health Canada for clinical-research protocols.
Ethics / IRB review remains a separate ~4–6 week benchmark clock.

Import: a research-use import permit connected to the COFEPRIS trial authorization. Confirm the current COFEPRIS procedure at filing — agency processes have been changing.

Until sponsors and CROs have measured real-world clocks across several submissions, keep Mexico on the watchlist with an asterisk. Parallelize ethics and regulator filings; do not bank the announcement as Panama-class speed.

Argentina — ANMAT (investigation is not registro)

ANMAT is one agency name on two files. Write them apart before anyone translates:

Investigation file. Clinical-investigation authorization for FIH or early feasibility, plus independent ethics under ISO 14155 and the Declaration of Helsinki, plus provincial oversight where required (for example Buenos Aires). Disposición ANMAT 7516/2025 Article 5 assigns clinical-investigation evaluation to the Dirección de Investigación Clínica. Published planning framework: 90-business-day statutory review target that pauses for RFIs.
Registro file. Sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including HELENA declaración jurada routes for eligible CE-marked Class I/II. Success criterion: a selling license — not a trial letter.

Import authorization links to the ANMAT trial approval through a licensed importer of record. Argentina’s import documentation is exacting. Reconcile every document before filing. A HELENA DDJJ or a cousin SKU’s registro does not move investigational kits.

Full dossier checklist: see the live ANMAT clinical-trial submission checklist.

Panama — MINSA (fast corridor, still two files)

Panama’s Ministry of Health (MINSA) oversees clinical investigations through the Dirección Nacional de Farmacia y Drogas on the live Panama hub language. Ethics review runs through institutional bioethics committees registered with the national CNBI. Published ethics band: about 3–5 weeks. Insurance exhibits belong in that packet.

Published Class III FIH geography language points at Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026 on the Panama Class III FIH guide — confirm those instruments at filing. Dollarized economy, English-capable sites, investigation units only.

Import authorization is tied to the MINSA trial authorization. Panama’s fast startup clock only holds if import runs in parallel with ethics and regulatory submissions. Commercial registro stays a separate MINSA market-access file.

Universal dossier core (assemble once)

Use the same core across all four desks, then layer country packets. Grounded in the live LATAM FIH submission-package checklist:

Section	Freeze once	Country layer
Protocol	Version, endpoints, stopping rules	Same version across agency + ethics packs
Investigator’s brochure / preclinical	Risk profile for first human use	Matches the article on the investigational list
Informed consent	Local language for ethics	Spanish (MX/AR/PA) or Portuguese (BR) — not the later commercial IFU
Insurance	Trial-related injury coverage	Territory and named parties match the sites
ISO 14155 monitoring plan	GCP bridge for foreign data	Design for 21 CFR § 812.28 inspectability if a U.S. file is intended
Investigational labeling + device list	Lot/serial accountability	Quantities match what import will request (BR: Comunicado Especial)
Importer of record	Legal name before ethics stamps	Document ties shipment to investigation authorization

How these approvals relate to FDA

A clean ANVISA, COFEPRIS, ANMAT, or MINSA investigation letter does not replace an inspectable trial master file. Foreign clinical data can be eligible for FDA submission and review under 21 CFR § 812.28 when the investigation meets the GCP conditions in that rule. ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. Eligibility is not a clearance prediction. Keep device accountability, deviation logs, monitoring reports, and ethics correspondence in one place from day one. See the live FDA 21 CFR 812.28 LATAM inspectability and FDA acceptance of LATAM FIH data pages.

Common failure patterns across all four

One LATAM Gantt bar. Panama’s corridor clock does not transfer to ANVISA or ANMAT.
Registro number on investigational freight. Commercial certificates do not clear FIH kits in Brazil, Mexico, Argentina, or Panama.
Ethics after agency. Sequential filing burns calendar the statutory targets never promised to absorb.
Importer named after first patient. Import then becomes the critical path ethics cannot fix.
Announcement clocks treated as measured clocks. Especially Mexico’s COFEPRIS reset — verify before you promise the board.

One-page gate before first patient

Country shortlist with indication-level patient flow — not just the fastest desk.
Authority map: investigation desk + ethics (+ provincial / CONEP / CNBI as applicable) versus commercial registro on a separate track.
Same protocol version across every packet.
Importer named, with the document that ties shipment to investigation authorization.
Device list complete, including accessories and authorized quantities.
ISO 14155 file owner who can produce monitoring, accountability, and ethics letters within 48 hours if FDA asks.

ANMAT clinical-trial submission checklist for medical device studies in Argentina

Sponsors keep asking what ANMAT requires for clinical trials in Argentina as if one ninety-day bar covered ethics, investigation authorization, investigational import, and later commercial registro. It does not. ANMAT is one agency name on two files. Confusing them is how an Argentina Gantt goes soft.

I am Julio Martinez-Clark, CEO of bioaccess®. This checklist is for medical-device clinical-investigation filings in Argentina. It is grounded in the live ANMAT trial authorization vs registro post, the investigational import guide, and the market-access hub. It is not a quote and not legal advice. Confirm every instrument against ANMAT’s current published texts before you file.

Separate the two ANMAT files first

Write two columns on one page before translators start:

Investigation file. ANMAT clinical-investigation authorization for a first-in-human (FIH) or early feasibility study (EFS), plus independent ethics review under ISO 14155 and the Declaration of Helsinki, and provincial oversight where it applies (for example Buenos Aires). Success criterion: authorized research use of the named investigational article.
Registro file (commercial, later or parallel only if truly in scope). Sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including the simplified declaración jurada (DDJJ) route for CE-marked Class I/II through HELENA, with a local authorized representative / Technical Director ANMAT will treat as responsible for that certificate. Success criterion: a selling license — not a trial letter.

If the board slide says “ANMAT approved,” ask which ANMAT. Trial authorization is not a selling license.

Governing desks on the investigation track

ANMAT — Dirección de Investigación Clínica. Disposición ANMAT 7516/2025 Article 5 assigns clinical-investigation evaluation to that directorate. The Colombia execution pillar already notes that disposition states no binding day-count for that evaluation desk in the same way some markets publish one; Argentina’s published planning framework for device investigations on our Argentina trial page remains the 90-business-day statutory review target that pauses for RFIs. FIH/EFS device studies often exceed that target. Treat 90 business days as a planning framework, not a guaranteed total start-up time.
Independent ethics committee. Protocol, Spanish informed consent, and investigator packet. Ethics is a gate on the trial track, not a commercial license.
Provincial oversight where required. File federal, ethics, and provincial packages in parallel when the study design allows it. Sequential filing adds calendar the statutory target never promised to absorb.
Investigational import. Authorization linked to the ANMAT trial approval, through a licensed importer of record, with a device-level manifest. A commercial registro number does not clear investigational kits. Argentina’s import documentation is exacting — reconcile every document before filing (see the regional import guide).

Submission checklist (investigation dossier)

Assemble the universal FIH core once, then layer Argentina’s desks. Do not invent form codes that are not on the live bioaccessla.com pages — use this operator checklist against ANMAT’s current published requirements at filing time.

Section	What to freeze	Operator check
Protocol	Version, endpoints, stopping rules, schedule of events	Same version across ANMAT, ethics, and provincial packs
Investigator’s brochure / preclinical	Risk profile for first human use	Matches the article on the investigational device list
Informed consent (Spanish)	Ethics-ready language for Argentina	Not the commercial IFU you will later lock on a registro
Case report form	Locked before site training	Version matches protocol
Insurance	Trial-related injury coverage in the form Argentina requires	Territory and named parties match the sites
ISO 14155 monitoring plan	GCP bridge for foreign data	If U.S. filing is intended, design for 21 CFR § 812.28 inspectability from day one
Investigational labeling	For clinical investigation only	Lot/serial traceability matches site accountability
Device / accessory list	Every unit that will sit in the accountability log	Quantities match what import will request
Importer of record	Legal name before ethics stamps the protocol	Document ties shipment to investigation authorization — not HELENA DDJJ, not a cousin SKU’s registro
Ethics + provincial letters	Independent committee; provincial filings where required	Keep correspondence in one trial master file

What this checklist is not

It is not the commercial Classes I–IV / HELENA map under Disposición 64/2025. That is the market-access track and the live ANMAT registration checklist.
It is not an importer-of-record substitute for a sanitary registration holder. Argentina is a strict single-IoR example on the commercial track (authorized representative under Disp. 64/2025). That holder conversation belongs on market access. It does not clear investigational freight for a FIH.
It does not claim ANMAT is a PAHO/WHO Level 4 authority, and it does not invent an ICH-member claim — those claims are not published on this site.

Import: investigational units are not the registro SKU

Hand-carry is not the plan. Formal, traceable importation tied to the trial authorization is required across Latin America; Argentina is not an exception.

If the Argentina FIH must support a U.S. file

Design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States): GCP, independent ethics review, and a device comparable to the version you will put in front of FDA. ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean ANMAT investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, ethics correspondence, and provincial letters in one place from day one. Eligibility of foreign data under § 812.28 is not a clearance prediction.

Common rejection / delay patterns

One 90-day bar for both desks. Treating the statutory trial review target as if it also covered Classes I–IV commercial registration. Higher-risk commercial work often runs several months on experience, not on the trial clock.
Registro number on investigational freight. Using a commercial ANMAT certificate for a predicate or related model to move FIH units.
One Spanish translation for both desks. Ethics/investigation language is not the commercial IFU ANMAT will later lock on a registro.
Importer named after first patient. Import documentation then becomes the critical path the ethics letter cannot fix.
RFI pause ignored on the Gantt. The 90-business-day target pauses for requests for information. Budget response time.

One-page gate before first patient in Argentina

Authority map: ANMAT investigation + independent ethics (+ provincial where required) versus commercial registro under Disp. 64/2025 / HELENA only if launch is truly in scope this year.
Same protocol version and same Spanish informed-consent text across federal, ethics, and provincial packages.
Investigational importer named, with the document that ties the shipment to the investigation authorization.
Device list complete, including accessories.
ISO 14155 file owner who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
Commercial holder (optional, separate): Argentine authorized representative / Technical Director kept off the FIH critical path until first patient is locked.

Frequently asked questions

What are ANMAT requirements for clinical trials in Argentina?

For devices, expect an ANMAT clinical-investigation file evaluated via the Dirección de Investigación Clínica (Disposición 7516/2025 Art. 5), independent ethics review, provincial filings where required, investigational labeling and import tied to the trial authorization, and an ISO 14155-ready trial master file. Commercial registro under Disposición 64/2025 / HELENA is a second petition.

Does the 90-business-day clock cover commercial registration?

No. The 90-business-day statutory target on our Argentina investigation pages is a planning framework for the trial review that pauses for RFIs. Classes I–IV registro is a separate file and clock.

Can we use a commercial ANMAT number to import FIH units?

No. Investigational units need import authorization linked to the trial approval. A registro number for a related commercial SKU does not clear the investigational article.

Is the registration holder the same as the trial importer?

Not automatically. Argentina’s commercial track is a strict single-IoR / authorized-representative posture under Disp. 64/2025. Name the trial importer for the investigation; keep the sanitary registration holder on the market-access track.

Will FDA accept Argentina FIH data?

Foreign clinical data may be eligible for FDA consideration under 21 CFR § 812.28 when GCP, ethics, and device comparability are documented. Eligibility is not a clearance or approval prediction.

September 16, 2026

How to get IRB (CEI) approval for a medical device study in Colombia

Sponsors keep asking how to get IRB approval for a medical device study in Colombia as if ethics were a single stamp that also clears INVIMA. It is not. In Colombia the ethics desk is a Comité de Ética en Investigación (CEI) approved by INVIMA, sitting at an IPS that holds a current Buenas Prácticas Clínicas (BPC) certificate. The investigation opinion and the import authorization are separate desks. Mixing them is how first patient slips a cycle.

I am Julio Martinez-Clark, CEO of bioaccess®. This is the Colombia ethics walkthrough for medical-device studies, grounded in the live Colombia clinical-trial execution pillar, the INVIMA clinical-trial submission checklist, and the universal LATAM FIH submission package. It is not a quote and not legal advice. Confirm every form against INVIMA’s current Investigación Clínica — Dispositivos page before you file.

What “IRB” means in Colombia

US sponsors say IRB. In Colombia the working term is CEI — an INVIMA-approved research ethics committee. The CEI reviews the protocol, informed consent, and investigator packet under the human-subjects rules in Resolución 8430 de 1993. The CEI letter is not an INVIMA investigation opinion, and it is not a Registro Sanitario.

Write three owners before you open a Spanish translation folder:

CEI / ethics. INVIMA-approved committee; initial study evaluation on form ASS-RSA-FM169.
INVIMA investigation opinion. For devices, the Sala Especializada de Dispositivos Médicos y Reactivos de Diagnóstico In Vitro (SEDMRDIV), supported since 20 September 2022 by the GICASE group under Resolución 2022035262. Forms ASS-RSA-FM085 / ASS-RSA-FM172.
Import of the investigational article. Exceptional importation under Decreto 4725 de 2005 Article 48(b), against a prior specialized-chamber opinion — not a commercial registro number on the airway bill.

If your Gantt has one bar labeled “Colombia IRB,” you do not have an ethics plan. You have a hope.

Site prerequisites the CEI will not waive

A Colombian interventional device study needs more than a friendly PI:

A CEI approved by INVIMA.
A site (IPS) with a current BPC certificate. INVIMA issues that certificate after verifying compliance with Resolución 2378 de 2008 through inspection visits. The certificate runs five years.
Evidence that the institution is registered under the Sistema Único de Habilitación with authorized pharmaceutical service, clinical laboratory, and sample-collection services inside the same habilitación. Contracting those services outside the habilitación adds documentation to every BPC modification.

INVIMA’s register of approved research ethics committees places them in Bogotá, Medellín, Cali, Floridablanca, and Montería, attached to established IPS and medical foundations. Bogotá, Medellín, and Cali remain the tier-1 clusters for most device programs. Replacing a site’s ethics committee is a formal BPC modification: a new-conditions verification visit and a written transfer plan agreed with sponsor, CRO, and both committees. Treat CEI selection as a critical-path item, not an afterthought.

Step-by-step: ethics before (or beside) the INVIMA file

Colombia is not Panama’s parallel Type II + MINSA corridor. Plan CEI, INVIMA concept, and import as sequential critical-path items unless your operator has a documented reason to overlap them. The measured INVIMA average footed on the Colombia execution pillar is 5.1 months to a definitive concept (approve or reject). There is no statutory day-count for that concept. Do not paste a fast-corridor ethics band onto Bogotá.

Freeze the protocol version that every desk will see. The universal FIH core already names protocol, investigator’s brochure, informed consent, case report form, insurance, and preclinical testing. Colombia’s country add-on is a procedure-risk matrix — procedural risk, not FDA-style design verification.
Pick the IPS and confirm BPC + CEI status on INVIMA’s published registers before contracting. Do not discover a lapsed BPC certificate after the consent is translated.
Draft Colombian informed consent for that CEI — regulatory Spanish adapted for the committee, not a U.S. IRB form with a machine translation stapled on.
File the CEI package with ASS-RSA-FM169 (initial study evaluation completed by the ethics committee) and the reconciled Spanish + English pack: protocol, IB/preclinical, risk management (ISO 14971) appropriate to class, IFU and investigator training, clinical-trial insurance covering Colombian subjects, investigator CVs and GCP certificates, site budgets and contracts running in parallel so activation is not the bottleneck after the opinion lands.
Keep the CEI letter and the SEDMRDIV file on the same investigation story. Stopping rules, device description, and the article you will import must match. Prototype authorization under Decreto 4725 de 2005 Article 36 is research and experimentation only — not health care use, not a commercial registro number.
Only then treat import as its own authorization under Article 48(b). The CEI stamp does not clear customs.

What the CEI packet must prove

Packet item	What it proves	Common stall
Protocol + stopping rules	Same investigation the SEDMRDIV will see	Version drift vs the INVIMA file
IB / preclinical	Risk profile for first human use	Thin bench package, hoping ethics will “fill gaps”
Colombian ICF	Subjects informed in local regulatory language	US IRB text with Spanish overlay
Insurance	Coverage for Colombian subjects	Policy that does not name the territory or runoff the CEI expects
Investigator docs	Qualified team at a BPC site	PI CV without current GCP evidence
Procedure-risk matrix	Colombia add-on on procedural risk	Treating it as a product design-verification dump

Timelines you can put on a board slide

CEI cadence — committee-specific. Confirm meeting frequency during site selection. This page does not invent a national CEI day-count.
INVIMA concept — measured average 5.1 months to a definitive concept; no statutory clock. Published approval and non-approval registers exist for device studies — read the non-approval register before you invent a “Colombia is unpredictable” narrative.
Import — after the specialized-chamber path that Article 48(b) requires. Plan it as its own bar.
Not law yet — the clinical-research framework bill filed in the Cámara in August 2025 would introduce tacit approval (7 calendar days common-risk / 30 high-risk, with FIH and novel implantables as high-risk). Do not put that clock in a diligence deck as if it were current INVIMA practice.

Common mistakes that burn ethics weeks

Treating CEI approval as if it were the INVIMA investigation opinion or Registro Sanitario.
Skipping BPC / habilitación checks, then losing weeks on a BPC modification mid-startup.
Filing a drug Protocolos en Línea path (tariffs 4070 / 4083) for a device SEDMRDIV file — wrong desk.
Assuming post-trial access is mandatory in Colombia. It is not. Resolución 2378 de 2008 and Resolución 8430 de 1993 contain no statutory post-trial supply duty; see the LATAM PTA operator map.
One workstream for FIH evidence and later commercial registro. Article 18(k) of Decreto 4725 de 2005 is why class IIb and III evidence and registration strategy belong in the same plan — not why they share one ethics form.

Frequently asked questions

How do I get IRB approval for a medical device study in Colombia?

Engage an INVIMA-approved CEI at an IPS with a current BPC certificate, file the ethics package (including ASS-RSA-FM169), and keep that packet aligned with the separate SEDMRDIV investigation file and Article 48(b) import path. The CEI letter alone does not authorize the study or the investigational shipment.

Is Colombia’s CEI the same as INVIMA authorization?

No. Ethics (CEI), INVIMA investigation opinion (SEDMRDIV / GICASE), and exceptional import are three desks under Decreto 4725 de 2005, Resolución 8430 de 1993, and the BPC regime in Resolución 2378 de 2008.

Which cities have INVIMA-approved ethics committees?

INVIMA’s published register places approved committees in Bogotá, Medellín, Cali, Floridablanca, and Montería. Tier-1 device work usually concentrates in Bogotá, Medellín, and Cali.

How long does Colombia ethics plus INVIMA take?

CEI timing is committee-specific. INVIMA’s measured average to a definitive concept is 5.1 months with no statutory day-count. Plan sequential desks unless you have a documented overlap plan.

Does every Colombian site need a BPC certificate?

Yes in practice for institutions running interventional research under INVIMA oversight. The certificate runs five years and depends on habilitación services inside the same institution.

September 16, 2026

Real Hospital Português de Beneficência em Pernambuco Recife: The NCT Campus String Is Not the ANVISA File
Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Real Hospital Português Recife as a bioaccess® client.

If you searched Real Hospital Portugues Recife first-in-human, Beneficencia Portuguesa Pernambuco clinical trial, Hospital Real Portugues Recife CRO, or “go direct Real Hospital Português Recife,” you followed a campus string ClinicalTrials.gov still publishes. Real Hospital Português de Beneficência em Pernambuco in Recife, Brazil, is a real named hospital-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.

This page is the named Recife Real Hospital Português de Beneficência em Pernambuco campus only. It is DISTINCT from Beneficência Portuguesa São Paulo / Real e Benemérita Associação Portuguesa de Beneficência (already live — do not near-dup collapse). Sharing a Português / Beneficência name is not a license to merge Recife and São Paulo. Real Hospital Português Recife is not Beneficência Portuguesa SP. Real Hospital Português Recife is not UFPE Recife. Real Hospital Português Recife is not Hospital do Câncer de Pernambuco.

Why the campus name wins the search — and why that is not a CRO

Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.
- Real Hospital Português de Beneficência em Pernambuco (Recife, Brazil) — canonical NCT string: ALL interventional n=8; DEVICE n=3. Example NCT IDs: NCT03141216, NCT04540302, NCT06096142.
Cite canonical ALL n=8 and DEVICE n=3. Do not clone Beneficência Portuguesa São Paulo, UFPE Recife, or Hospital do Câncer de Pernambuco onto this slug. Recife campus only.

Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this hospital as a client site.

That is the leak: a founder searching Real Hospital Português Recife first-in-human finds ALL n=8 (DEVICE n=3) without finding ANVISA. A named hospital campus is still a site. An NCT location row is not a CRO.

The site is the site. The CRO is the operator.

A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

What the hospital can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing service line.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the hospital is not built to own for an investigational device:
- ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at Real Hospital Português Recife is not a Beneficência Portuguesa São Paulo file.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a campus-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.
Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

How ANVISA actually works (the short version)

Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

Do not smear the hospital

Real Hospital Português de Beneficência em Pernambuco Recife is a serious named Brazilian campus on the public registry. ALL n=8 and DEVICE n=3 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

What the CRO still does after you have the campus on a slide
1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
3. Importer of record and device accountability.
4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.

Colombia is still on the map

Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

Frequently asked questions

Can I contract Real Hospital Português Recife directly for a device FIH?

You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

Did bioaccess® run the NCT IDs listed here?

No public bioaccess® case-study page names this hospital. We will not invent that claim. This page intercepts the search; it does not claim the studies.

Is this the same page as Beneficência Portuguesa São Paulo?

No. Beneficência Portuguesa / Real e Benemérita Associação Portuguesa de Beneficência São Paulo is already live — different city. This page is the Recife Pernambuco campus only.

Did bioaccess® run NCT03141216?

No. We cite it as facility evidence. We will not invent a sponsor or a PI.

Next step

If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Recife sibling (do not merge): UFPE Recife.

Julio G. Martinez-Clark, CEO · bioaccess®
September 15, 2026
Univás Pouso Alegre: The NCT Campus String Is Not the ANVISA File
Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Univás Pouso Alegre as a bioaccess® client.

If you searched Univas Pouso Alegre first-in-human, Universidade Vale do Sapucai clinical trial, Univas CRO, or “go direct Univás Pouso Alegre,” you followed a campus string ClinicalTrials.gov still publishes. Univás in Pouso Alegre, Brazil, is a real named university-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.

bioaccess®’s position is simple and it is not adversarial: the university is the site. The First-in-Human CRO still owns ANVISA, CEP / CONEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the university still have to rebuild that stack. An NCT location row is not a CRO.

This page is the named Pouso Alegre Univás campus. It is DISTINCT from Federal University of Santa Maria, Federal University of Bahia Salvador, UFF Niterói, and UFPI / Federal University of Piaui clones (skip UFPI Fisioterapia). Sharing a university / Brazil string is not a license to collapse them. Univás Pouso Alegre is not UFSM. Univás Pouso Alegre is not UFBA. Univás Pouso Alegre is not UFPI.

Why the campus name wins the search — and why that is not a CRO

Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.
- Univás (Pouso Alegre, Brazil) — canonical NCT string: ALL interventional n=10; DEVICE n=3. Example NCT IDs: NCT03200938, NCT04870294, NCT05270538.
Cite canonical ALL n=10 and DEVICE n=3. Do not clone UFSM, UFBA, UFF, or UFPI onto this slug. Skip Phototherapy lab department_lab strings and UFPI Fisioterapia clones.

Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this university as a client site.

That is the leak: a founder searching Univás Pouso Alegre first-in-human finds ALL n=10 (DEVICE n=3) without finding ANVISA. A named university campus is still a site. An NCT location row is not a CRO.

The site is the site. The CRO is the operator.

A named university can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

What the university can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing service line.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the university is not built to own for an investigational device:
- ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation at Univás Pouso Alegre is not a UFSM file and is not a UFPI file.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a campus-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.
Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

How ANVISA actually works (the short version)

Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.

All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

Do not smear the hospital

Univás Pouso Alegre is a serious named Brazilian campus on the public registry. ALL n=10 and DEVICE n=3 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator.

What the CRO still does after you have the campus on a slide
1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
2. Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
3. Importer of record and device accountability.
4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.

Colombia is still on the map

Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

Frequently asked questions

Can I contract Univás Pouso Alegre directly for a device FIH?

You can try. The university can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

Did bioaccess® run the NCT IDs listed here?

No public bioaccess® case-study page names this university. We will not invent that claim. This page intercepts the search; it does not claim the studies.

Is this the same page as Federal University of Santa Maria or Federal University of Piaui?

No. federal-university-santa-maria-fih is already live from leftover 57. UFPI / Federal University of Piaui Fisioterapia clones are skipped. This page is Univás Pouso Alegre only.

Did bioaccess® run NCT03200938?

No. We cite it as facility evidence. We will not invent a sponsor or a PI.

Next step

If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Brazil sibling (do not merge): Federal University of Santa Maria.

Julio G. Martinez-Clark, CEO · bioaccess®
September 15, 2026
IECED Guayaquil: The NCT Campus String Is Not the ARCSA File
Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ARCSA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim IECED Guayaquil as a bioaccess® client.

If you searched IECED Guayaquil first-in-human, Instituto Ecuatoriano de Enfermedades Digestivas clinical trial, IECED Ecuador CRO, or “go direct IECED Guayaquil,” you followed a campus string ClinicalTrials.gov still publishes. Instituto Ecuatoriano de Enfermedades Digestivas (IECED) in Guayaquil, Ecuador, is a real named institute-campus string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ARCSA file.

bioaccess®’s position is simple and it is not adversarial: the institute is the site. The First-in-Human CRO still owns ARCSA, CEISH ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the institute still have to rebuild that stack. An NCT location row is not a CRO.

This page is the named Guayaquil IECED campus. It is DISTINCT from English-alias ecuadorian-institute-digestive-diseases-guayaquil-fih and academy-tertiary-ieced-guayaquil-fih clone strings — do not publish those as separate ranks. Sharing Guayaquil / IECED is not a license to multiply pages. IECED is not a Quito National Police UDV string. IECED is not a generic Ecuador fold.

Why the campus name wins the search — and why that is not a CRO

Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.
- Instituto Ecuatoriano de Enfermedades Digestivas (IECED) (Guayaquil, Ecuador) — canonical NCT string: ALL interventional n=8; DEVICE n=4. Example NCT IDs: NCT05640401, NCT06102980, NCT06264466.
Cite canonical ALL n=8 and DEVICE n=4. Do not clone English IECED alias ranks or academy-tertiary-ieced onto this slug. Spell ARCSA on first use in agency copy via leftover_lib (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria).

Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this institute as a client site.

That is the leak: a founder searching IECED Guayaquil first-in-human finds ALL n=8 (DEVICE n=4) without finding ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria). A named institute campus is still a site. An NCT location row is not a CRO.

The site is the site. The CRO is the operator.

A named institute can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

What the institute can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing service line.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the institute is not built to own for an investigational device:
- ARCSA. ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) is the national file for an investigational device study in Ecuador. CEISH ethics still has to sit before enrollment. A hallway conversation on this campus is not that stack. Live Ecuador blogs already use 4–8 week ethics and 30–90 day submission language; we will not invent a new median here. We do not invent an Ecuadorian legal entity. A hallway conversation at IECED Guayaquil is not an ARCSA / CEISH clearance and is not an English-alias IECED clone file.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a campus-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.
Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

How ARCSA actually works (the short version)

Use clinical-trials-ecuador. ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) — a decentralized Ministry of Health agency — authorizes clinical trials and classifies devices (I, IIa, IIb, III). Every study also needs written approval from a Human Research Ethics Committee (CEISH — Comité de Ética de Investigación en Seres Humanos) before enrollment. That hub does not invent a new Ecuador day-count; live Ecuador blogs already use 4–8 week ethics language and 30–90 day submission language under Ministerial Agreement 0075-2017 and later reforms. Ask for a protocol-specific calendar. Commercial sanitary / device classification is a second file. We will not invent PAHO/WHO Level 4 standing for ARCSA. We do not invent an Ecuadorian legal entity on this page. Headline ~30% lower (experience-based) program cost versus typical US/EU baselines is already on that hub — not a campus quote we invent here.

Ask for a protocol-specific calendar. A hospital email is not ARCSA clearance. bioaccess® manages the file. That is CRO work, not site work.

All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

Do not smear the hospital

IECED Guayaquil is a serious named Ecuadorian campus on the public registry. ALL n=8 and DEVICE n=4 are registry volume, not a punchline. Do not invent a PI. Use the site when the protocol fits. Hire the operator. We do not invent an Ecuadorian legal entity on this page.

What the CRO still does after you have the campus on a slide
1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
2. Protocol, IB, ICF, insurance, and the ARCSA / ethics packet.
3. Importer of record and device accountability.
4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.

Colombia is still on the map

Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

Frequently asked questions

Can I contract IECED Guayaquil directly for a device FIH?

You can try. The institute can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ARCSA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

Did bioaccess® run the NCT IDs listed here?

No public bioaccess® case-study page names this institute. We will not invent that claim. This page intercepts the search; it does not claim the studies.

Is this the same page as Ecuadorian Institute of Digestive Diseases (English alias) or academy tertiary IECED?

No. Those are alias / department_lab clone strings for the same Guayaquil IECED campus. This page is Instituto Ecuatoriano de Enfermedades Digestivas (IECED) Guayaquil only — do not publish the English alias or academy-tertiary ranks separately.

Did bioaccess® run NCT05640401?

No. We cite it as facility evidence. We will not invent a sponsor or a PI.

Next step

If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Country operator page: clinical trials in Ecuador (ARCSA / CEISH file).

Julio G. Martinez-Clark, CEO · bioaccess®
September 15, 2026

Blog

What the FDA Breakthrough Devices Program Actually Is

The Two Eligibility Criteria Your Device Must Meet

Criterion 1: Serious or Life-Threatening Condition

Criterion 2: More Effective Than Available Alternatives

When to Apply and What to Submit

What Breakthrough Designation Actually Gets You

The Gap Between Designation and Authorization

How Breakthrough Designation Connects to Your FIH Strategy

Common Reasons Designation Requests Are Denied

After Designation: Keeping the Benefits Active

Frequently Asked Questions

Build the Evidence Package Your Designation Demands

What Happens Immediately After Submission

The 30-Day Review Window

Conditional Approval: What It Means and What to Do Next

IDE Amendments and Protocol Changes

Site Activation After IDE Approval

FDA IDE Approval and the OUS Clinical Strategy

Reporting Obligations That Begin at Approval

What the IDE Approval Letter Does Not Cover

Using the IDE Approval Window Productively

After Approval: The Path to First Patient Enrolled

Frequently Asked Questions

What Comes Next

Two Chile files — write them apart first

Where Chile sits on the FIH map

What ISP owns on the trial track

Ethics under Law 20.120

Submission checklist (investigation dossier)

Import: investigational units are not the Decree 25 SKU

If the Chile FIH must support a U.S. file

Do not smear the hospital — and do not skip ISP

Common rejection / delay patterns

One-page gate before first patient in Chile

Related reading on bioaccessla.com

Write four columns before translators start

Same question, four different clocks

Brazil — ANVISA (investigation + import are two layers)

Mexico — COFEPRIS (reset language ≠ measured clock yet)

Argentina — ANMAT (investigation is not registro)

Panama — MINSA (fast corridor, still two files)

Universal dossier core (assemble once)

How these approvals relate to FDA

Common failure patterns across all four

One-page gate before first patient

Related reading on bioaccessla.com

What Is an FDA Q-Submission?

Why File a Pre-Sub Before Your IDE?

When to File Your Pre-Sub

What to Include in Your Pre-Sub Package

Device Description and Intended Use

Proposed Clinical Indication

Draft Study Design and Protocol Outline

Risk Analysis Summary

Proposed Regulatory Pathway

Your Specific Questions

Common Pre-Sub Mistakes That Delay IDE Filings

Submitting Without a Defined Regulatory Pathway

Asking Too Many Questions

Conflating OUS Data with IDE Exemption

Underestimating Meeting Preparation

How OUS Early Clinical Data Fits Into Your Pre-Sub Strategy

The Pre-Sub to IDE Sequence in Practice

What FDA Looks for in a Strong Pre-Sub Package

Connecting Pre-Sub Strategy to Your FIH Execution Plan

Frequently Asked Questions

Separate the two ANMAT files first

Governing desks on the investigation track

Submission checklist (investigation dossier)

What this checklist is not

Import: investigational units are not the registro SKU

If the Argentina FIH must support a U.S. file

Common rejection / delay patterns

One-page gate before first patient in Argentina

Related reading on bioaccessla.com

Frequently asked questions

What are ANMAT requirements for clinical trials in Argentina?

Does the 90-business-day clock cover commercial registration?

Can we use a commercial ANMAT number to import FIH units?